Literature DB >> 35088383

Transcriptome-guided resolution of tumor microenvironment interactions in pheochromocytoma and paraganglioma subtypes.

S Batchu1, A Hakim2, O S Henry3, J Madzo4, U Atabek2, F R Spitz2, Y K Hong2.   

Abstract

BACKGROUND: Pheochromocytomas and paragangliomas (PCPG) are rare catecholamine-secreting endocrine tumors deriving from chromaffin cells of the embryonic neural crest. Although distinct molecular PCPG subtypes have been elucidated, certain characteristics of these tumors have yet to be fully examined, namely the tumor microenvironment (TME). To further understand tumor-stromal interactions in PCPG subtypes, the present study deconvoluted bulk tumor gene expression to examine ligand-receptor interactions.
METHODS: RNA-sequencing data primary solid PCPG tumors were derived from The Cancer Genome Atlas (TCGA). Tumor purity was estimated using two robust algorithms. The tumor purity estimates and bulk tumor expression values allowed for non-negative linear regression to predict the average expression of each gene in the stromal and tumor compartments for each PCPG molecular subtype. The predicted expression values were then used in conjunction with a previously curated ligand-receptor database and scoring system to evaluate top ligand-receptor interactions.
RESULTS: Across all PCPG subtypes compared to normal samples, tumor-to-tumor signaling between bone morphogenic proteins 7 (BMP7) and 15 (BMP15) and cognate receptors ACVR2B and BMPR1B was increased. In addition, tumor-to-stroma signaling was enriched for interactions between predicted tumor-originating delta-like ligand 3 (DLL3) and predicted stromal NOTCH receptors. Stroma-to-tumor signaling was enriched for interactions between ephrins A1 and A4 with ephrin receptors EphA5, EphA7, and EphA8. Pseudohypoxia subtype tumors displayed increased predicted stromal expression of genes related to immune-exhausted T-cell response, including those for inhibitory receptors HAVCR2 and CTLA4.
CONCLUSION: The current exploratory study predicted stromal and tumor through compartmental deconvolution and yielded previously unrecognized interactions and putative biomarkers in PCPG.
© 2021. Italian Society of Endocrinology (SIE).

Entities:  

Keywords:  Ligand–receptor interactions; Paraganglioma; Pheochromocytoma; Pseudohypoxia; RNA deconvolution; Tumor microenvironment

Mesh:

Substances:

Year:  2022        PMID: 35088383     DOI: 10.1007/s40618-021-01729-8

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Pan-Cancer Analysis of Ligand-Receptor Cross-talk in the Tumor Microenvironment.

Authors:  Umesh Ghoshdastider; Neha Rohatgi; Marjan Mojtabavi Naeini; Probhonjon Baruah; Egor Revkov; Yu Amanda Guo; Simone Rizzetto; Angeline M L Wong; Sundar Solai; Tin T Nguyen; Joe Poh Sheng Yeong; Jabed Iqbal; Puay Hoon Tan; Balram Chowbay; Ramanuj Dasgupta; Anders J Skanderup
Journal:  Cancer Res       Date:  2021-02-05       Impact factor: 12.701

2.  PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.

Authors:  Jennifer H Yearley; Christopher Gibson; Ni Yu; Christina Moon; Erin Murphy; Jonathan Juco; Jared Lunceford; Jonathan Cheng; Laura Q M Chow; Tanguy Y Seiwert; Masahisa Handa; Joanne E Tomassini; Terrill McClanahan
Journal:  Clin Cancer Res       Date:  2017-06-15       Impact factor: 12.531

3.  Highly specific multiplexed RNA imaging in tissues with split-FISH.

Authors:  Jolene Jie Lin Goh; Nigel Chou; Wan Yi Seow; Norbert Ha; Chung Pui Paul Cheng; Yun-Ching Chang; Ziqing Winston Zhao; Kok Hao Chen
Journal:  Nat Methods       Date:  2020-06-15       Impact factor: 28.547

4.  Predicting tumor purity from methylation microarray data.

Authors:  Naiqian Zhang; Hua-Jun Wu; Weiwei Zhang; Jun Wang; Hao Wu; Xiaoqi Zheng
Journal:  Bioinformatics       Date:  2015-06-25       Impact factor: 6.937

5.  Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.

Authors:  Jacques W M Lenders; Quan-Yang Duh; Graeme Eisenhofer; Anne-Paule Gimenez-Roqueplo; Stefan K G Grebe; Mohammad Hassan Murad; Mitsuhide Naruse; Karel Pacak; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2014-06       Impact factor: 5.958

6.  Age-related differences of immune infiltrates in pheochromocytomas and paragangliomas.

Authors:  S Batchu
Journal:  J Endocrinol Invest       Date:  2020-10-08       Impact factor: 4.256

Review 7.  Programmed death ligand 2 in cancer-induced immune suppression.

Authors:  Esdy N Rozali; Stanleyson V Hato; Bruce W Robinson; Richard A Lake; W Joost Lesterhuis
Journal:  Clin Dev Immunol       Date:  2012-04-29

8.  Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma.

Authors:  Yan Zhou; Dong Yang; Qingcheng Yang; Xiaobin Lv; Wentao Huang; Zhenhua Zhou; Yaling Wang; Zhichang Zhang; Ting Yuan; Xiaomin Ding; Lina Tang; Jianjun Zhang; Junyi Yin; Yujing Huang; Wenxi Yu; Yonggang Wang; Chenliang Zhou; Yang Su; Aina He; Yuanjue Sun; Zan Shen; Binzhi Qian; Wei Meng; Jia Fei; Yang Yao; Xinghua Pan; Peizhan Chen; Haiyan Hu
Journal:  Nat Commun       Date:  2020-12-10       Impact factor: 14.919

9.  High-definition spatial transcriptomics for in situ tissue profiling.

Authors:  Gökcen Eraslan; Fredrik Salmén; Johanna Klughammer; Linnea Stenbeck; Sanja Vickovic; Denis Schapiro; Tarmo Äijö; Richard Bonneau; Ludvig Bergenstråhle; José Fernandéz Navarro; Joshua Gould; Gabriel K Griffin; Åke Borg; Mostafa Ronaghi; Jonas Frisén; Joakim Lundeberg; Aviv Regev; Patrik L Ståhl
Journal:  Nat Methods       Date:  2019-09-09       Impact factor: 28.547

Review 10.  Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma.

Authors:  Maran Ilanchezhian; Abhishek Jha; Karel Pacak; Jaydira Del Rivero
Journal:  Curr Treat Options Oncol       Date:  2020-08-29
View more
  1 in total

1.  Favorable outcome in advanced pheochromocytoma and paraganglioma after hypofractionated intensity modulated radiotherapy.

Authors:  Z Gu; K Hu; Y Liang; F Zhang; A Tong; X Hou
Journal:  J Endocrinol Invest       Date:  2022-09-19       Impact factor: 5.467

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.